VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ATRC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ATRCAtriCure, Inc.
$58.54$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ATRC logo

AtriCure, Inc.

ATRC
NASDAQ · Medical Devices
$58.54
At close - Nov 6, 4:00 PM EST - USD
Market Cap$2.98B
P/E196.0x
52W High$66.02
Volume613.51K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Growing Revenue Meets Thin Margins and Heavy Dilution

AtriCure's revenue has grown from $116.3M in Q2 2024 to $154.4M in Q3 2026, with year-over-year growth of 15.0% in the latest quarter, suggesting durable demand for its surgical ablation franchise.

GrowthExpanding
ProfitabilityModerate
ValuationExpensive
TechnicalsHealthy
Explore valuation models
MARKET ACTION

ATRC price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

9/12 Beats

EPS beat 9 of last 12 quarters

02

Valuation risk

+466% Peers

P/E is 466% above peer median

03

Market leadership

RS 97 · Leader

High momentum (Outperforming 97% of market)

04

Healthy Uptrend

Uptrend

Price > 50DMA > 200DMA

Next CatalystEstimated earnings · Feb 3

Market performance

Price History →

Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ATRC+49.07%
S&P 500 (^GSPC)+7.63%
1-Year Return
ATRC+85.84%
S&P 500 (^GSPC)+9.69%
3-Year Return
ATRC+54.62%
S&P 500 (^GSPC)+61.32%
5-Year Return
ATRC-30.97%
S&P 500 (^GSPC)+50.78%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
196.0x
Forward P/E
541.5x
EV/EBITDA50th %ile
73.9x
FCF YieldCash Flow
1.9%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
196.0x
63.8x
100th· High
EV/EBITDA
73.9x
105.9x
50th· Fair
Price/FCF
51.4x
39.1x
100th· High
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$10.45-82.1%
Base (Fair)$17.58-70.0%
Bull$18.32-68.7%
$10.45 Bear$17.58 Base$18.32 Bull
Current Market Price: $58.54
Trades at a 233.0% premium to Base DCF ($17.58)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$535M+14.9% YoY
Net income FY25
-$11M+74.4% YoY
Free cash flow FY25
$48M+529.0% YoY
Operating margin FY25
-0.6%+8.0 pts YoY
ROIC (FY25)-0.6%
Avg ROIC 5Y-1.9%
ROE (TTM)2.9%
Piotroski Score5 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate9/12 (75%)
Revenue Beat Rate9/12 (75%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 3, 2026
$0.17+408.0%
vs -$0.06
$154M+2.2%
vs $151M
Q3 2026
Jul 23, 2026
$0.18+10878.4%
vs -$0.00
$154M+1.2%
vs $152M
Q2 2026
May 5, 2026
$0.00+103.1%
vs -$0.07
$141M+1.1%
vs $140M
Q1 2026
Feb 17, 2026
$0.06+249.9%
vs -$0.04
$141M+0.6%
vs $140M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Defense World·Oct 14, 2026
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Taiwan Semiconductor Manufacturing stock on September 22nd. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF

Business Wire·Oct 13, 2026
AtriCure to Announce Third Quarter 2026 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2026 financial results on Tuesday, November 3, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, November 3, 2026, to discuss its third quarter financial results. Those interested in liste.

Defense World·Sep 25, 2026
AtriCure (NASDAQ:ATRC) Reaches New 12-Month High – Here’s What Happened

AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) shares reached a new 52-week high during trading on Wednesday. The company traded as high as $60.99 and last traded at $60.9210, with a volume of 76652 shares traded. The stock had previously closed at $58.83. Wall Street Analysts Forecast Growth Several brokerages have recently weighed in on

Zacks Investment Research·Sep 14, 2026
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Filtered for AtriCure, Inc.More Headlines
04

Compare before deciding

Benchmark ATRC against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for AtriCure, Inc. (ATRC)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ATRC logoATRCAtriCure, Inc.Current
$58.54$2.98B195.9814.88%2.52%2.93%—
NVCR logoNVCRNovocure Ltd
$13.28$1.54B-12.748.28%-16.78%-35.81%—
IRTC logoIRTCiRhythm Technologies, Inc.
$90.22$2.96B-77.3926.24%-4.52%-22.8%—
BEAT logoBEATHeartBeam, Inc.
$0.40$22.31M-1.05——-686.78%—
ABT logoABTAbbott Laboratories
$109.93$191.48B40.645.67%9.75%9%2.14%
MDT logoMDTMedtronic plc
$101.80$130.7B25.018.43%13.93%10.51%2.78%

Compare ATRC vs Peers

AtriCure, Inc. (ATRC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVCR

Most directly comparable listed peer for ATRC.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare ATRC against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVCR, IRTC, BEAT, ABT

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ATRC SEC Filings & Documents

AtriCure, Inc. (ATRC) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 3, 2026·SEC

Material company update

Jul 23, 2026·SEC

Material company update

May 19, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 19, 2026·SEC

FY 2025

Feb 14, 2025·SEC

FY 2024

Feb 16, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 4, 2026·SEC

FY 2026

Jul 27, 2026·SEC

FY 2026

May 6, 2026·SEC

Get notified when ATRC posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ATRC Frequently Asked Questions

AtriCure, Inc. (ATRC) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is AtriCure, Inc.'s revenue?

AtriCure, Inc. (ATRC) reported $589.8M in revenue over the trailing twelve months. Revenue was $534.5M in fiscal year 2025. That is 2690% more than the $19.2M of fiscal year 2004.

How fast is AtriCure, Inc. growing?

AtriCure, Inc. (ATRC) grew revenue by 13.8% over the trailing twelve months, compared with the twelve months before.

Is ATRC profitable?

Yes. AtriCure, Inc. (ATRC) earned $14.9M in net income over the trailing twelve months (a 2.5% net margin).

Dividend & Returns
What is ATRC's return on equity?

AtriCure, Inc. (ATRC) had a return on equity (ROE) of 2.9% over the trailing twelve months. That is below the market's typical 10-15%.

What is AtriCure, Inc.'s free cash flow?

AtriCure, Inc. (ATRC) generated $57.9M in free cash flow over the trailing twelve months.

What if you invested $1,000 in ATRC back in 2004?

Total return calculator · dividends reinvested · 22+ years of data

See returns →